

9

Research Article

FIMD based model validation approaches for Rheumatoid arthritis and associated cardiovascular complications: an attempt towards translational competence

Trupti Dubey¹, Kirti V. Patel¹

1. The Maharaja Sayajirao University of Baroda, Kalabhavan Campus, Vadodara 390001 Gujarat India

Corresponding author: Kirti V. Patel (kirtipatel.pub2023@gmail.com)

Academic editor: Mikhail Korokin • Received 06 February 2024 • Accepted 17 April 2024 • Published 30 June 2024

Citation: Dubey T, Patel KV (2024) FIMD based model validation approaches for Rheumatoid arthritis and associated cardiovascular complications: an attempt towards translational competence. Research Results in Pharmacology 10(2): 73–82. https://doi.org/10.18413/rrpharmacology.10.446

Abstract


Introduction: The present *in-vivo* experiment was designed to validate newly developed rat models for Rheumatoid Arthritis (RA) as well as cardiovascular complications in RA for translational competence of disease with clinical situation. The FIMD (Framework to Identify Models for Disease) method based on etiology, pathophysiology, symptomatology, and response to therapeutic interventions was used to compare these models sensitized with primary (CFA, bovine collagen type II) and secondary inducing agents (high fat diet, lipopolysaccharide) in different combinations.

Material and Methods: Twenty-four Wistar male rats (four groups/n=6) were taken after prevalidation, where a large dataset was analyzed by using statistical methods (one way ANOVA, repeated Measure ANOVA). Among these groups, two best models from RA representative groups and two best models from cardiovascular complications in RA generated groups were taken for final comparison and validation by the same weight score method for obtaining a percentage similarity and validity score using a radar plot based on FIMD to get the best suited model.

Results and Discussion: The findings of this study on the basis of FIMD showed that the collagen (0.1 mL) +lipopolysaccharide (10 μ g/mL) induced model is closely fit for preclinical events of RA, with the highest validity score (82%) among all groups and the collagen (0.1 mL)+ lipopolysaccharide (10 μ g/mL)+HFD represents a validated model (95%) for co-morbid cardiovascular complications in RA

Conclusion: The developed and validated models were a fresh attempt using different inducers sequentially to culminate the emerging issue of extra organ manifestation in existing RA via a similar pathway, which can be a contributor to future research in drug discoveries in pharmacology.

Graphical abstract



Keywords

adjuvant (CFA), collagen, high fat diet, lipopolysaccharide, rheumatoid arthritis, validation

Introduction

The use of animal models as a small instrumental replica of human diseases is a basic biomedical tool. Here the model (rat/mouse/rabbit/guinea pig/dog/monkey) in pharmacology is something that mimics the human physiology and pathological conditions at certain levels (Lilley et al. 2020). In any research, the concept, findings, and conclusions should be able to generate the same results on recreating the model fundamentals with all variables (Dobbin et al. 2016), which is considered validity. An animal model is considered to be valid if it resembles the human conditions adequately and contributes valuable information to our knowledge of biology and medicine, including the discovery and development of new drugs to match preclinical and clinical events (Sams-Dodd 2006).

The present investigation was developed to create a rat model that can represent RA as well as the extra organ manifestations of RA. In this line of search, many studies were conducted to provide insight about RA and associated manifestations, but none of them is specific representation of cardiovascular complications in RA (Cassotta et al. 2020; Hong et al. 2020). To provide a scientifically proven solution, the current study was designed to get to the bottom of two major issues: 1) model resemblance with human disease by developing and validating experimental rat models for two situations; i) Rheumatoid Arthritis using Complete Freund's Adjuvant (CFA) and Bovine collagen type-II as primary inducing agents with lipopolysaccharide (LPS) as secondary inducing agent to get complete insight into etiology, progression, and maximum human resemblance. ii) Rheumatoid Arthritis with cardiovascular complications using a high fat diet (HFD) and LPS (Dubey and Chorawala 2015) in existing CFA and collagen models for combining RA with cardiovascular complications via metabolic dysbiosis and to minimize the translational gap between preclinical and clinical findings.

Multiple models were developed and compared to select the best models for both of these situations, applying traditional biostatistics in pharmacology, which shows the selectivity of four models. Furthermore, the FIMD method (Ferreira et al. 2019) was adopted for model validation, which provides standardization, integration, and the facility of model comparison on eight domains; epidemiology, symptomatology and natural history criteria (SNH) matching with human disease onset, biochemical validation, pharmacological validation, histological validations, endpoint validation and genetic validation to provide the internal and external endpoints (Ferreira et al. 2020).

Model validation in preclinical research

Validity indicates how refined your research is, in terms of proving the correctness of your hypothesis. Hindrances in model resemblance to human etiology and symptomatology are affected with the common laboratory limitation and the improper selection of a hypothesis which is based only on predictive data (Scannell et al. 2022). If a model selected is unable to prove modality and reproducibility, it can fail to level the gap between preclinical and clinical trials which is the most prominent reason of this defeat. The flawed preclinical data without a validation tool are inadequate to generate the sufficient data for further proceeding. These concepts of model validation are based on:

Predictive-validity – The basic target of predictive validity is to check to what extent the demonstrated model, in particular species, replicates the human disease condition. The predictive validity is based on the evaluation of the end points (parameters) based on statistical tools in terms of reliability and relevance. Reliability is assessed by calculating the inter-laboratory reproducibility and intra laboratory repeatability;

Face validity – Face validity is logical validity, which is primarily the theoretical consideration of the procedure as to what extent it is similar to the set hypothesis (Silverman et al. 2020);

Constrict validity and target validity – The target under investigation at the time of recreation should have a similar role in the disease model as in the clinical situation (Tadenev and Burgess 2019).

The basic validation strategies were given by Frank Sams-Dodd (2006), Wilner et al. (2011), and Tinneke Denayer et al. (2014), in which model selection is based only on external validity criteria such as species, strain, complexicity level and duration of treatment for an animal selected for studies.

These basics can be used to avoid the lower-level faults in conceptualization of a model. However, an animal model should also replicate the internal validity (symptomatology, disease-specific criteria, subjectivity and reproducibility), which is a prime requisite for the resemblance of clinical conditions. On the other side, if they are adequately designed and conducted, animal models can contribute valuable information to our knowledge of biology and medicine, including the discovery and development of new drugs (Deore et al. 2019).

On the basis of all the above-discussed points, the sequences in this study were conceptualized on two problem statements mentioned in relevance to RA model development.

The first and foremost challenge was to develop an

animal model which is similitude to clinical (human like) complications arisen in RA, which was done by:

a) Comparing primary inducing agents CFA and Collagen

b) Comparing secondary inducing agent LPS with primary inducing agent (CFA and Collagen) in model developed for RA.

The challenge in model development was to take one more step in relation to complexity of diseases as incorporation of clinical co-morbid conditions (RA along with CVD). In attempted preclinical model development, cardiovascular complications were induced via the incorporation of one more secondary inducing agent; high-fat diet with CFA, collagen and LPS model to link the metabolic dysbiosis with already immune compromised animals to produce metabolic insults to crosslink inflammation and immune responses.

Materials and Methods

Animals

All experiments were carried out on male wistar rats (150-200 g), obtained from registered breeders of experimental animals. Animals were housed in well-controlled conditions of temperature ($22\pm2^{\circ}C$), humidity ($55\pm5\%$), and a 12-hrs light-dark cycle with free access to a conventional laboratory diet in all groups and high fat diet (HFD) in specific groups with purified water *ad libitum*.

All the mentioned studies were approved by the Institutional Animal Ethics Committee (IAEC), Pharmacy Department. Faculty of Pharmacy, The M. S. University of Baroda, vide Minutes MSU/IAEC/2015-16/1661 dated 30/12/2016, MSU/IAEC/2018-19/1802 dated 29/12/2018 and MSU/IAEC/2019-20/1904 dated 21/08/2019 in accordance with the guidance of the Committee for the Control and Supervision of Experiments on Animals (CCSEA) and The Prevention of Cruelty to Animals act (PCA), 1960, Department of Animal Husbandry and Dairying, Ministry of Fisheries Animal Husbandry and Dairying Government of India (DAHDMoFAH&D).

Experimental methods

This experimental research was framed on the basis of the results obtained with the following studies:

Study design I – Development of animal models for replication of Rheumatoid arthritis, where RA models were developed using CFA alone, CFA with LPS, collagen alone, and collagen with LPS.

Study design II – Development of animal models for replication of RA and CV complications using high fat diet with selected models from RA developed groups.

Methodology for Study design I

Objective one fulfilled by using two separate inducers considered as primary stimulants in different groups of animals:

CFA (Complete Freund's Adjuvant (CFA - each mL contains 1 mg heat killed and dried *Mycobacterium tuberculosis* in 0.85 mL paraffin oil and 0.15 mL mannide monooleate) purchased from Sigma-Aldrich, Bangalore, India, was used to sensitize the animals on day 0 where 0.1 mL of CFA was injected by sub planter route on the left hind paw of rats to induce RA (Kollias et al. 2011). The total observation period for this study was 28 days.

Bovine Collagen (Type II) was purchased from Chondrex Inc Redmond, WA, USA, supplied by Krishgen Biosystem Mumbai, India. It was used in different sets of animals, where premix of CFA and collagen (1:1) (Miyoshi and Liu 2024) was used to induce RA in rats. On day 0, animals were sensitized with injecting this premix by sub planter route on the left hind paw. In this experiment, the study period was framed for 42 days.

To further stimulate the disease severity, lipopolysaccharide (cell wall components of the gram negative bacteria Escherichia coli O111:B4) purchased from Sigma-Aldrich, Bangalore, India, was used as a secondary inducer. Here, LPS was dissolved in saline to get the desired concentrations and given to animals via the subcutaneous route to prevent sepsis-like conditions. LPS sensitization was done from days 14 to 28 in 0.1 mL dose by subcutaneous route in rats pre challenged with CFA as an inducing agent in concentrations of 0.1, 0.5, and 10 µg/mL. Sensitization was started after the first sign of immunological intervention as evidenced by increased neutrophil and lymphocytes in hematological investigations on day 12 of the study. In collagen-induced arthritis groups also, the rats were sensitized with LPS (0.5, 0.1, and 10 μ g/mL doses from day 14 to 42 by subcutaneous route (See Supplement I for detailed procedure).

Methodology for study design II

The final selected groups from study 1 - group Va (CFA+LPS10 μ g/mL) and group Vb (CIA 0.1 mL+LPS 10 μ g/mL) were carried out for further assessment here.

All the animals selected in this protocol were fed with modified high fat diet (Dubey and Chorawala 2015) throughout the study period for creating atherogenic environment in animals. Lard rich diet (30%) was used in this study to activate the metabolic dysbiosis with the other expects of inflammation to link it with atherogenic episodes (See Supplement file I for further details about the models).

CFA and CIA were used here also for primary induction, whereas for secondary sensitization, LPS and HFD were used. The two groups mentioned above were compared with the following group of animals; group VI (CFA 0.1 mL+HFD), which received CFA 0.1 mL on day 0 along with HFD given for 28 days. Group VII (CFA 0.1 mL+HFD+LPS 10 µg/mL) was sensitized with CFA (0.1 mL) on day 0 and further sensitized with LPS (10 μ g/ mL), and HFD was given to the animals for 28 days. Group VIII (CIA 0.1 mL+HFD) received CIA (0.1 mL) on day 0 with further feeding with HFD for 42 days and group IX (CIA 0.1 mL+HFD+LPS 10 µg/mL) received CIA (0.1 mL) on day 0 and further sensitized with LPS (10 µg/mL) on day 14 till day 42, and animals were fed with HFD throughout the study period (42 days). All the parameters for assessment of RA were performed at different time points for 28 days in CFA groups and 42 days in CIA groups, respectively. All the developed groups are initially summarized in Fig. 1.

Notation: For better understanding in succeeding sections, the final compared groups will be denoted as - group Va (CFA 0.1 mL+LPS 10 μ g/mL) as Model I, group Vb (CIA 0.1 mL+LPS 10 μ g/mL) as Model II (Representing RA models), group VII (CFA 0.1 mL+HFD+LPS 10 μ g/mL) as Model III and group IX (CIA 0.1 mL+HFD+LPS 10 μ g/mL) as Model IV (representing RA along with CVD).

Evaluation parameters for prevalidation

The estimated parameters were analyzed for prevalidation on the basis of observational outcomes of physical estimations (Paw volume, Arthritic index, Arthritic score), biochemical estimations (Rheumatoid Factor (RF), ESR, C-RP, IL-6, TNF-a, CBC, Homocysteine and Anti-CCP, Triglyceride levels, Cholesterol, HDL, LDL levels, atherogenic index) and TLR-4 activation (Luo et al. 2020) by the statistical data. Moreover, pilot studies for estimation of dose response and variability of different inducing agents (CFA, collagen, LPS, HFD) were performed with exploratory experiments (treatment responses, hypothesis correction via p value correction using post hoc tests in ANOVA) (Barnett et al. 2022) and photography, X-Ray and histopathology (bone, vastus medialis and biceps femoris muscle) were made as confirmatory tests for evaluating the development of the model in both the groups sensitized with CFA and collagen with and without LPS and HFD addition.

Methods for final model validation

As these statistical data are predictive values, and the outcome is insufficient to give a model that can be called validated, so among all nine groups, four groups: Va (CFA 0.1 mL+LPS 10 μ g/ml), Vb (CIA 0.1 ml+LPS 10 μ g/ml), VII (CFA 0.1 ml+HFD+LPS 10 μ g/ml) and IX (CIA 0.1 mL+HFD+LPS 10 μ g/mL) were carried forward for external validity measures.

Here, a decision regarding the selection of an optimum/appropriate dose of LPS (among three concentrations of 0.1, 0.5 and 10 μ g/mL) was made by processing the obtained data for significance using ANOVA as primary evaluation tool for pharmacological comparison. The selected models were carried forward for validation based on the Framework to Identify Models of Disease (FIMD) given by Guilherme S. Ferreira et al. (2020).

Model validation methods

Framework to identify models for disease

This is a questionnaire-based validation system in which models can be compared and evaluated for eight domains; epidemiology, symptomatology and natural history – SNH, biochemical validation, aetiological validation, pharmacological validation, histological validation, endpoint validation, and genetic validation.

These domains were firstly defined in a questionnaire, and the questions were framed according to disease severity and progression using the mentioned domains. Each domain was given the same weighing score. Questions (Table 1) were also answered separately for all subsections on the basis of the five answer patterns suggested (yes, yes completely, yes partially, unclear, and no).

After answering the questions with suitable grades, the summation of all the scores of sections and subsections of the individual domain was done to get the final score, and it was subtracted from the actual domain score to get ratio for plotting the radar chart, which is one of the comparative tools for analyzing multivariate data (See Supplement II for questionnaire and details of calculation steps provided in supplement III and IV).




Figure 1. Study designs for development, selection and validation of models for RA and CVD in RA. *Note:* In this figure, the flow of model development is depicted where: Step I – Induction of RA in rats using CFA and collagen as primary inducers with and without LPS as secondary inducer was performed; Step II – Selection of models for RA was made on the basis of results of ANOVA used as pre validation tool; Step III – Here as depicted in flow chart, selected groups from RA induced models were further developed using CFA and collagen as primary inducers with LPS and HFD as secondary inducers to develop cardiovascular complications in existing RA; Step IV – models for cardiovascular complications in RA were further analyzed using prevalidation tool to select best fit model for CVD in RA; Step V – Same weight score method was applied to validate the models on the basis of FIMD method to compare and validate the developed models for RA and Cardiovascular complications in RA for human resemblance.

The framework was adopted and the questions were framed using the reference of the framework, but some extra points were added according to the need of the study. The questions were more focused on the Rheumatoid Arthritis and cardiovascular complications in the selected models with questions of clinical relevance (this is a sample questionnaire, See Supplement III and IV for detail).

Statistical analysis

Models with both situations (RA and cardiovascular complications in RA) were selected by prevalidation using statistical methods (one way ANOVA and Repeated measure ANOVA) using GraphPad Prism software, where values are expressed as Mean±SEM. Boneferroni's, Dunnett's, and Tukey's *post hoc* tests were used for comparisons between each group. Significant values were compared at p<0.05, p<0.01, p<0.01 (all the details are attached as Supplement file I).

The data obtained by ANOVA were considered as primary data and further compared by same weight score

method of FIMD where all the domains were scored equally with subsections to make total score 100 to get a ratio which was used to interpret the radar plot. Here, Microsoft excel was used to generate a 2D radar plot, and the values (calculated ratio) for each domain were analyzed. The radar chart gives each domain an axis, and we can compare the models by putting the ratio obtained after giving a suitable score to each question of each domain and calculating it through the steps mentioned in the Supplement. To check the similar domains in models, similarity factors and uncertainty factors were also calculated which can account for improvements in experimental design.

The final scores were calculated by putting these values in radar plot and compared to check the levels of validation by each domain assigned. If the final percentage of the model lies between 0 and 40%, the model is considered *insufficiently validated*. If model scores are 41-60%, then it is considered *slightly validated*. If the model scores within 61-80%, it is *moderately validated*, and if the scores are within 81-100%, it is *highly validated*.

Table 1. Questionnaire for comparison of models developed for cardiovascular complications in RA

| 1. Name of population (three/cubics) 1.1 Sets or objet bits simulate the discuss in the relevant age groups (inventic, adult or aging) 1.2 Is an odd able to simulate the discuss in the relevant age groups (inventic, adult or aging) 1.2 Is an odd able to simulate the discuss in the relevant age groups (inventic, adult or aging) 1.2 Is an odd able to simulate the discuss in the relevant age groups (inventic, adult or aging) 1.3 Is an odd able to simulate the discuss in the relevant age groups (inventic, adult or aging) 1.3 Is an inventic, adult or aging in the adult of adult | Questions for RA with CVD Model | SW |
|--|--|------|
| 12 Is fue nocki able to simular the disease in different genous (nocki able or aging) 15 Is fue nocki able to simular the disease in different genous 15 Is fue nocki able to simular the disease in different genous 15 Is model able to simular the disease symptom, if so which one 13 Is fuenced able to simular the disease symptom, if so which one 13 Is fuenced able to simular the disease symptom, if so which one 13 Is fuenced able to simular the disease one 14 Is fuenced able to simular the disease one 15 Is concil able to simular the disease one 15 Is concil able to simular the disease one 15 Is concil able to simular the disease one 15 Is concil able to simular the disease one 15 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 16 Is concil able to simular the disease one 17 Is concil able to simular the disease one 18 Is concil able to simular the disease one 18 Is concil able to simular the disease one 18 Is concil able to simular the disease one 18 Is concil able to simular the disease one 18 Is concil able to simular the disease one 19 Is the able to the simular to the simular to the simular disease 10 Is concented to the simular to the simular disease 10 Is the able to the disease on the the disease | 1. Epidemiology | |
| 1.3 https://weistance.it.endlet.org/it.en | 1.1 Nature of population (indeed/Outored) 1.2 Is the model able to simulate the disease in the relevant age groups (invenile, adult or aging) | |
| 21 is noted able io minic human disease symptoms, if so which one 183 12 immunological markers in cardiovascular complications 183 12 immunological markers in cardiovascular complications 183 12 immunological markers in cardiovascular complications 183 12 immunological markers in the marker in the marker of the markers in the marker in the markers | 1.3 Is the model able to simulate the disease in the refer and age groups (difference, addit of aging) | |
| 2.1 Inflammatory markers 1.38 2.1 J consublishing markers for cardiovascular complications 1.38 2.1 J consolithing markers for cardiovascular complications 3.8 2.2 Jonatar History criteria matching with human disease onet 0.83 2.2 J Dense progression 0.83 2.2 J Dense progression 0.83 2.2 J Metarblic dysbiosis 0.83 2.2 J Metarblic dysbiosis 0.83 2.2 A Metabolic dysbiosis 0.81 2.2 Conductiv distores replicated in model similar to human conditions? If yes which one 4.16 3.1 Scondary lesion 0.41 3.2 Overlap synchrome (Digestion of digits) 1.44 3.3 Low organization 1.46 3.4 Avacanoxi 1.46 3.1 Phorematic humandroses minute the pathophysiology of the lawan disease 1.46 3.1 Interessed differenceme markers (CH = RL, ArkCP, Hyp) 1.38 3.1 Interessed differenceme markers related on pathophysiology of the disease 0.69 3.3 Kowow progroson findserse 0.69 3.3 Sowow progroson findsese< | 2. Symptomatology and natural history | 12.5 |
| 21. Jamoshogical markers 21. Jamoshogical markers for cardboxcalar complexations 23. Considing, markers for cardboxcalar complexations 23. Conside, markers for cardboxcalar complexations 23. La Time of neast 22. Diration of symptoms 23. Diration of symptoms 23. Conside, markers for cardboxcalar complexations 23. Conside, and the symptoms 23. Conside, and the symptoms 23. Conside, and the symptoms 23. Constraints 24. Constraints 25. Constraints 26. Constraints 27. Constraints 27. Constraints 28. Constraints 29. Constraints 29. Constraints 20. Constraints 20. Constraints 20. Constraints 24. Constraints 25. Constraints 26. Constraints 27. Constraints 28. Constraints 29. Constra | 2.1 Is model able to mimic human disease symptoms, if so which one | |
| 21.3 Consoliation markers for cardiovascular complexations1322.1 Struct History criteria matching with human disease onset4.1622.1 Trune of onset0.8322.2 Discuse progression0.8322.3 Duration of symptoms0.8322.4 Metholic dybinosis0.8322.5 Outrol functions replicated in model similar to human conditions? if yes which one4.1623.1 Secondary lesions1.0423.2 Octurbary disconter (Digestion of digits)1.0423.3 Lot cardio and functions replicated in model similar to human conditions? if yes which one1.623.3 Lot cardio and functions replicated in model similar to human disease1.623.3 Lot cardio and functions replicated in model similar to human disease1.623.4 Status1.0423.5 Lot cardio and functions replicated in model similar to human disease1.623.1 Increased influentiatory markers (CR). ESA, Arthritic Index.)1.3823.1 Increased influentiatory markers (CR). TSC, Cholesterol, Atheroxiccloric index.)1.3823.3 Decisities0.6923.3 Valuing diffuscities related to pathophysiology of the function diffuscities0.6923.3 Valuing diffuscities related to pathophysiology of the disease0.6923.3 Valuing diffuscities related to mathophysiology of the disease0.6923.4 Valuing diffuscities related to mathophysi | | |
| 22 Natural History criteria matching with human disease onset 416 22 I Time of onest 0.83 22.2 I Time of onest 0.83 22.2 Discase progression 0.83 22.2 Discase progression 0.83 22.3 Distation of symptoms 0.83 22.4 Metholic dyshoids 0.83 22.5 OUT infittation 0.83 23.1 Secondary lesions 0.46 23.1 Secondary lesions 0.46 23.2 Output with a symptoms 0.46 23.3 Ust origin manifestation 0.46 23.3 Ust origin manifestation 0.46 23.4 Secondary dividiation 1.25 11 Increased inframatory markers (RP, FSR, Arthrite Infex) 1.38 12 Increased inframatory markers (RP, FSR, Arthrite Infex) 1.38 23 Discover progression of disease 4.16 23 Nonvor progression of disease 4.16 23 Nonvor progression of disease 4.16 23 Nonvor progression of disease 4.16 23 A structure markers balance similar to human for Rheamatoid Arthrite? If yes which one 6.25 24 I Status distribution 1.25 23 Structure gram markers table dyshoids 6.69 23 A which formation 1.25 24 Distructure gram distribution of disease 1.25 25 Distructure gram dis | - | |
| 2.1 True of onsit0.832.2 J Descar progression0.832.3 Descar progression0.832.3 Descar progression0.832.4 Methole (Aybinois)0.832.5 Conduct (actions replicated in model similar to human conditions? if yes which one1.162.3 Lex Conduct (actions replicated in model similar to human conditions? if yes which one1.162.3 Lex Conduct (actions replicated in model similar to human conditions? if yes which one1.162.3 Lex Conduct (actions replicated in model similar to human disease1.162.3 Lex Conduct (actions replicated in model similar to human disease1.163. Biochemical validation1.253. Lo creased inflammatory markers (CR). ESR, Arthritic Index.)1.383. Lo creased inflammatory markers (CR). ESR, Arthritic Index.)1.383. J Increased inflammatory markers (CR). ESR, Arthritic Index.)1.383. J Increased inflammatory markers (CR). ESR, Arthritic Index.)1.383. J Nahlard distates0.693.3 So Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.693.3 Chearty0.69 <td></td> <td></td> | | |
| 22.2 Discusse progression0.8322.3 Duration of symptoms0.8322.4 Mutholic dyshoiss0.8322.4 Mutholic dyshoiss0.8322.5 OUT infiltration0.8323 Co-Morbid Conditions replicated in model similar to human conditions? if yes which one1.1623.1 Secondary Jesions1.0423.2 Startin organ manifestation1.0423.3 Startin organ manifestation1.0423.4 Startin organ manifestation1.0423.4 Startin organ manifestation1.0423.5 Hartin organ manifestation1.0531.1 Increased inframatory markers (RPC, RP, RA, Arthici Index)1.3831.2 Increased inframatory markers (RPC, RP, RA, Arthici Index)1.3832.1 Dorbatics factoring in markers (RPC, RP, RA, Arthici Index)1.3832.2 Summer progression of disase0.6933.3 Kowap regrossion tradies related to puthophysiology of the disease0.6933.3 Starbating comparison of disase0.6933.3 Starbating comparison of disase0.6933.3 Starbating comparison of disase0.6933.3 Contage (Starbating Cardina)0.6933.3 Contage (Starbating Cardina)0.6933.3 Starbating Cardina0.6933.3 Starbating Cardina0.6933.3 Starbating Cardina0.6933.3 Contage (Starbating Cardina)0.6933.3 Starbating Cardina0.6933.3 Starbating Cardina0.6933.3 Starbating Cardina0.6933.3 Starbating Cardina0.6933.3 Cardina0.624.1 Co-Clu | | |
| 2.2.4 Methodic dysbiosis0.832.2.5 GUT infirmation0.832.3 Co-Morbid Conditions replicated in model similar to human conditions? If yes which one4.162.3.1 Secondary lesions1.042.3.2 Overlap syndhomic (Digession of digits)1.042.3.2 Startar ogrim numerication1.042.3.3 Extra ogrim numerication1.042.3.4 Starta ogrim numerication1.042.3.4 Starta ogrim numerication1.043.1.6 Startar ogrim numerication1.043.1.7 Increased infirmandory matters (CRF LSR, Arthuric Index)1.383.1.8 Increased infirmandory matters (CRF, ESR, Arthuric Index)1.383.1.3 Increased infirmandory matters (CRF, ESR, Arthuric Index)1.383.2 Startar ogrim carkers (CRF, ESR, Arthuric Index)1.383.3 Increase in screetions0.693.3 Stavour progromic matters (CRF, ESR, Arthuric Index)0.693.3 Stavour progromic index (CRF, CL, Chelscreet, Atheroselenteine)0.693.3 Stavour progromic index (CRF, CL, Chelscreet)0.693.3 Stavour progromic index (CRF, CL, CL), Matter (CRF)0.693.3 Stavour progromic index (CRF)0.624.14 Co-Cl in | 2.2.2 Disease progression | |
| 22 5 GUT infitmation0.8323 5 GC-Morbit Conditions replication in model animal to human conditions? if yes which one0.1623 1 Secondary lesions1.0423 1 Storn organ manifestation1.0423 2 Storn organ manifestation1.0423 1 Storn organ manifestation1.043 Biochemical validation1.253 Biochemical validation1.383 1 Increased inflammatory markers (CRP. ESR, Arthritic Index)1.383 1 Increased inflammatory markers (CRP. CRS, CAC Pt yo)1.383 1 J Increased inflammatory markers (CRP. CRS, CAC Pt yo)1.383 1 J Increased inflammatory markers (CR, CAC Pt yo)1.383 1 J Increased inflammatory inflammatory inflamma?4.163 3 Lowakers behaves inflaming to human?0.603 2 D othese PD markers behaves inflaming to human?0.603 3 S Donsin0.603 4 Marking discase similar to human for Rheumatoid Arthritis? If yes which one6.254 1 Is the activality of the discase similar to human for Rheumatoid conditions? If yes which one6.254 1 S Adapraphic displinition1.254 1 S Adapraphic thronges1.254 | 2.2.3 Duration of symptoms | 0.83 |
| 22 Co-Morbid Conditions replicated in model similar to human conditions? if yes which one 4.16 23.1 Secondary lesions 1.04 23.2 Orthar syndhome (Digestion of digis) 1.04 23.3 Extra cogn manifestation 1.04 23.4 Strong manifestation 1.04 23.5 Usin cogn manifestation 1.05 31. Biochemical validation 1.25 31. Biochemical validation 1.25 31. Biochemical validation 1.25 31. Discessed interrogenic markers (INF at L-6, ACCP, Hyc) 1.38 31. Discessed interrogenic markers (INF at L-6, ACCP, Hyc) 1.38 32.2 Do these IPD markers (INF at L-6, ACCP, Hyc) 1.38 33.1 Validating distantial to human for Research at the second the disease 0.69 33.2 Do thise IPD markers (INF at L-6, ACCP, Hyc) 0.99 33.3 Validue formation 0.69 33.3 Validue formation 0.69 33.3 Protesse in second bacterity to human for Research at the second discese in th | 2.2.4 Metabolic dysbiosis | |
| 2.1 Secondary lesions 1.04 2.3 Solverlap synome (Digestion of digits) 1.04 2.3 Solverlap synome (Digestion of digits) 1.04 2.3 Secondary lesions 1.04 2.3 Secondary lesions 1.04 2.3 Secondary lesions 1.04 3.1 Increased influmatory markers (CRP, ESR, Arthritic Index) 1.38 3.1 Increased influmatory markers (CRP, ESR, Arthritic Index) 1.38 3.2 Derivation and theoregatic markers (TGP, TC, Cholsterand, Athrosolecotic index) 1.38 3.2 Differest and harmatory markers (CRP, ESR, Arthritic Index) 1.38 3.2 Differest and harmatory markers behave similarly to human? 4.16 3.3 Stowner prognostion differest to pathophysiology of the disease 0.69 3.3 Stowner prognostion markers behave similarly to human? 0.69 3.3 Stowner prognostion differest to pathophysiology of the disease 0.69 3.3 Stowner prognostion of disease 0.69 3.4 Actiologion valid | | |
| 2.2 Overlap syndrome (Digestion of digits)1042.3 Evtra organ manifestation1042.3 Evtra organ manifestation1043.1 Shochemical validation1253.1 Pharmacodynamic biomarkers mimic the pathophysiology of the human disease4.163.1 Increased influmenatory markers (CRP-ESR, Arhite Index)1383.1 Increased influmenatory markers (CRP-ESR, Arhite Index)1383.1 Discense of theoregoins markers related to pathophysiology of the disease4.163.1 Shoresed of theoregoins markers related to pathophysiology of the disease0.693.2 Shores PD markers behave similarly to human?0.693.3 Increase in scretcions0.693.3 Increase in scretcions0.693.3 Increase in scretcions0.693.3 Obesity0.693.3 Obesity0.693.3 Obesity0.693.3 Obesity0.693.4 Katological validation1.254.1 Is the attrology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1 2 Schale division1.254.1 2 Schale division1.254.1 2 Schale division1.254.1 2 Schale division1.254.1 2 Schale division1.254.2 Schale division1.254.3 Event or activation1.254.4 Schale division1.254.3 Event or activation1.254.4 Schale division1.254.4 Schale division1.264.3 Schale division1.264.3 Schale division1.264.4 Schale di | | |
| 2.3 Extra organ manifestania1042.3 A Steatosis1043 Biochemical validation12.53 Biochemical validation12.53 Biochemical validation1381 I Increased inflammatory markers (CRF, EJSR, Arthritic Index)1383 I I Increased inflammatory markers (CR, CC, CB, Hyc)1383 Biochemical validation1383 D I Increased inflammatory markers (CR, CC, Chockterol, Atheroselerotic index)1383 D I Increased inflammatory markers (CR, CC, Chockterol, Atheroselerotic index)1383 D I Increase in socretions0693.3 S Lowns prognositic markers related to pathophysiology of the disease0693.3 S A Noulie formation0693.3 S Oncessiti markers related to pathophysiology of the disease0693.3 S Noutier formation0693.3 S Oncessiti organism of disease0693.3 Concessi en secretions0693.3 Oncessiti organism of the secretions0693.4 Noulie formation1254 Li S Li S the actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one1254 Li S Li S the actiology of the disease similar to human for RA and co-morbid condition? If yes which one1254 Li S the actiology of the disease similar to human for RA and co-morbid condition? If yes which one1264 Li S the actiology of the disease similar to human for RA and co-morbid condition? If yes which one1254 Li S the actiology of the disease similar to human for RA and co-morbid condition? If yes which one1264 Li S the actiology of the disease similar to hu | - | |
| 3. Biochemical validation 12.5 3. Biochemical validation 416 3.1.1 Increased inflammatory markers (CRP, ESR, Arthritic Index) 1.38 3.1.2 Increased inflammatory markers (CRP, ESR, Arthritic Index) 1.38 3.1.2 Increased inflammatory markers (CRP, ESR, Arthritic Index) 1.38 3.1.2 Increased inflammatory markers behave similarly to human? 4.16 3.2.2 Number progression of disease 0.69 3.3.1 Working disability 0.69 3.3.2 Symmetric progression of disease 0.69 3.3.3 Howing fromotion 0.69 3.3.4 Nothly formation 0.69 3.3.5 Obesity 0.69 3.3.6 Marabiolic dyshosis 0.69 3.3.6 Marabiolic dyshosis 0.69 4.1 A triots eatiology of the disease similar to human for Rheumatoid Arthritis? If yes which one 6.25 4.1 Cyckine activation (NFA-rq, IL-6) 1.25 4.1 A triots engine for visus mediaits 1.25 4.1 A triots engine for visus mediaits 1.25 4.1 A triots engine visus mediaits 1.25 4.1 A triots engine visus mediaits 1.25 4.1 A triots engine visus activation 1.2 | 2.3.3 Extra organ manifestation | |
| 31. Pharmacodynamic biomarkers minic the pathophysiology of the human disease 4.16 31. Increased information markers (CRF, ESG, Arbitric Index) 1.38 31. 2. Increased afterogenic markers (CR, ESG, Arbitric Index) 1.38 32. Do these PD markers behave similarly to human? 4.16 33. Narking discibulity 0.69 33. 1 Walking discibulity 0.69 33. So Neares 0.69 33. A located in exerctions 0.69 34. A located avaluation in the numan for Rheumatoid Arthritis? If yes which one 6.25 41. 1 Sytica leading of vistus mediation 1.25 41. 2 Colic lumification (NEC, IL-6) 1.56 42. Disability 1.56 42. 1 Site has ediology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25< | 2.3.4 Steatosis | 1.04 |
| 31.1 Increased inflammatory markers (CRF, ESR, Arthritic Index) 1.38 32.1 Increased inflammatory markers (TG, TC, Cholesterol, Atherosclerotic index) 1.38 33.1 Stressed atherospenic markers (TG, TC, Cholesterol, Atherosclerotic index) 1.38 32.1 Do these PD markers behave similarly to human? 4.16 33.1 Stressen (account of disease 0.69 33.1 Symmetric progression of disease 0.69 33.3 Notating fromation 0.69 33.3 Notating fromation 0.69 33.3 Notating fromation 0.69 33.5 Obesity 0.69 34.1 Stresse instance human for Rheumatoid Arthritis? If yes which one 6.25 41.1 Cyckine activation (ACCP generation and Hye activation) 1.25 1.1 Stribut length of vistus medialis 1.25 41.1 Stribut length of vistus medialis 1.25 42.1 Staboligraphytic changes 1.25 43.1 Stribut length of vistus medialis 1.25 43.2 Metapholic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool) 1.56 | 3. Biochemical validation | |
| 31.2 Increased immunological markers (TIA, C. Cher, Hyc) 1.38 31.3 Increased interception indersocientol, theresocientol index) 1.38 32.1 Do these PD markers behave similarly to human? 4.16 33.1 Walking dischilty 0.69 33.1 Walking dischilty 0.69 33.2 Structures in secretions 0.69 33.3 Increase in secretions 0.69 33.4 Nukling dischilty 0.69 33.4 Nukling dischilty 0.69 33.4 Nukling dischilty 0.69 33.4 Natholic dysbiosis 0.69 33.5 Obesity 0.69 33.4 Natholic dysbiosis 0.69 4.4 Actiological validation 1.25 4.1 I Cychine activation (TNF-a, IL-6) 1.25 4.1 1 Cychine activation (ACCP generation and Hyc activation) 1.25 4.1 2 Cell infiltration (ACCP generation and Hyc activation) 1.56 4.2 Ste bacteriology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25 4.2 Bit bacteriology of the disease similar to human for RA and co-morbid conditions? If yes which one 1.56 4.2 Ste bacteriology of the disease similar to human for RA and co-morbid conditions? If yes which one 1.56 4.2 Ste bacteriology of the | | |
| 1.3 Increased atheragenic markers (TG, TC, Cholesterol, Atherosclerotic index)1.382.3 Do these PD markers belave similarly to human?4.1633 Known prognostic markers related to pathophysiology of the disease4.163.3 Invalking disability0.693.3 Symmetric progression of disease0.693.3 At Nodule formation0.693.3 So therase in secretions0.693.3 So therase in secretions0.693.3 So therase in secretions0.693.3 So therase in secretions0.693.3 So therase in secretions0.694. Actiological validation1.254. I Is the sectiology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254. 1 2 Cell infiftmition (ACCP generation and Hyc activation)1.254.1 3 Fibre length of vistus medialis1.254.1 4 Shore length of vistus medialis1.254.1 5 Radiorgn/fuc changes1.254.2 1 Disability1.564.2 3 Receptor activation (TR-H, NLRP-3)1.564.2 4 Habolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2 4 Seceptor activation (TR-H, NLRP-3)1.564.2 4 therate offective drugs also infective in this model?4.165.3 1 Are effective drugs also infective in this model?1.385.3 1 Cell drug1.385.3 1 Cell drug 11.385.3 1 Cell drug 31.385.3 1 Cell drug 31.385.3 1 Cell drug 31.385.3 1 Cell drug 31.385.3 1 Cell drug 41.66< | | |
| 32 Do these PD markers behave similarly to human? 416 33 Known prognostic markers related to pathophysiology of the disease 416 3.1 Walking disability 0.69 3.3 Shown prognostic markers related to pathophysiology of the disease 0.69 3.3 Shown prognostic markers related to pathophysiology of the disease 0.69 3.3 Morease in sceretons 0.69 3.3 A Moule formation 0.25 3.5 Obesity 0.69 3.5 A Metabolic dysbiosis 0.69 4.4 celiological validation 1.25 4.1 Is the actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one 6.25 4.1 2 Celi infiltration (ACCP generation and Hye activation) 1.25 4.1 4 Fibre length of vistus medialis 1.25 4.2 1 State actiology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25 4.2 1 State actiology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25 4.2 1 State actiology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25 4.2 1 State actiology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25 4.2 1 State actiology of the disease similar to human for RA and co-morbid conditions? If | | |
| 3.1 Walking disability0.693.3 2 Symmetric progression of disease0.693.3 2 Symmetric progression of disease0.693.3 A Increase in secretions0.693.4 Notuble formation0.693.5 Obesity0.693.6 Metabolic dysbiosis0.694.1 Stubolic dysbiosis0.694.1 Stubolic dysbiosis0.694.1 Stylokine activation (NPF-q, IL-6)1.254.1 I Stribe length of vistus medialis1.254.1 J Cell infiltration (ACCP generation and Hye activation)1.254.1 A Fibre length of bicpes femoris1.254.1 A Fibre length of bicpes femoris1.254.1 A Fibre length of bicpes femoris1.254.1 Stubolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2 A teceptor activation (ITL-4, NLRP-3)1.565.1 Are effective drugs in humans also effective in this model?4.165.1 Test drug 11.385.2 Test drug 21.385.3 Test drug 31.385.4 Test drug 31.385.5 Test drug 31.385.1 Test drug 41.256.1 Histopathology of heart1.667.1 Hadrographic changes2.87.1 Are dredictive drugs in intrastings of action and acting on different pathway been tested in this model?4.165.1 Are traffective drugs in intrastings of action and acting on different pathway been tested in this model?4.166.1 Histopathology of heart1.25 | 3.2 Do these PD markers behave similarly to human? | |
| 3.1 2 Symmutric progression of disease0.693.3.3 Increase in secretions0.693.3.4 Nodule formation0.693.3.5 Obesity0.693.3.5 Obesity0.693.3.5 Obesity0.693.3.5 Obesity0.694 Actiological validation1.2.54 I Is the actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1.1 Cytokine activation (NCP-q. IL-6)1.254.1.2 Cell infiltration (ACCP generation and Hyc activation)1.254.1.4 Fibre length of Vistus medialis1.254.1.4 Fibre length of biceps femoris1.254.1.5 Radiographic changes1.254.1.6 Radiographic changes1.254.1.7 Station and infibrition (CLR, A, NLRP-3)1.564.2 A texto argue manifestation1.564.2 A Extra orgue manifestation1.565.1 Nuch one (Methortexate)1.565.1 Nuch one (Methortexate)1.385.3 Test drug 31.385.3 Test drug 31.385.3 Test drug 21.385.3 Test drug 21.385.3 Test drug 21.386.1 Histopathology of heart4.166.1 Histopathology of stats medialis and biceps femoris muscle4.166.1 Histopathology of stats medialis and biceps femoris muscle4.166.1 Histopathology of operation and stifters in muscles resemble the ones found in humans? If yes which one4.166.1 Histopathology of operation and stifters comparable to the clinical endpoints?2.087.1 Are dreg with different mechanisms | 3.3 Known prognostic markers related to pathophysiology of the disease | 4.16 |
| 3.3 Increase in secretions0.693.3.4 Nodule formation0.693.3.4 Nodule formation0.693.3.6 Metabolic dysbiosis0.693.3.6 Metabolic dysbiosis0.693.4 Metabolic dysbiosis0.694.1 Let actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1.2 Cyclin encirvation (NTA-rq, IL-6)1.254.1.2 Cyclin encirvation (NTA-rq, IL-6)1.254.1.3 Fibre length of vistus medialis1.254.1.4 Fibre length of biceps fermoris1.254.1.5 Radiographic changes1.254.1.5 Itabibility1.564.2 Is the acticlogy of the disease similar to human for RA and co-morbid conditions? If yes which one6.254.2.1 Subability1.564.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.4 Extra organ manifistation1.565.1 Arc effective drugs in humans also effective in this model?4.165.1 Arc effective drugs also ineffective in this model?4.165.1 Arc effective drugs also ineffective in this model?4.165.3 Test drug 11.385.3.2 Test drug 21.385.3.3 Test drug 31.386.11 Histopathology of heart4.166.12 Histopathology of heart4.166.13 Histopathology of heart4.166.14 Histopathology of heart4.166.15 Histopathology of heart4.166.12 Histopathology of beart4.166.13 Histopathology of beart6.257.1 Are the endpoin | 3.3.1 Walking disability | 0.69 |
| 3.4 Nodule formation0.693.5 Obesity0.693.5 Obesity0.693.5 Obesity0.694 Actiological validation12.54.1 Is the actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1 Is Cytokine activation (TNF-α, IL-6)1.254.1 Set Cytokine of vistus medialis1.254.1 Set Cytokine diversity of the disease similar to human for RA and co-morbid conditions? If yes which one6.254.1 Set Roitengraphic changes1.254.1 Set Roitengraphic changes1.254.2 Set biolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.565.2 Actesto activation (TLR-4, NLRP-3)1.565.4 Pharmacological validation12.55.1 Are effective drugs in humans also effective in this model?4.165.1 Ji which one (Methotrexet)1.385.2 Are ineffective drugs also ineffective in this model?4.165.3 I ter drug 11.385.3 Test drug 21.386.1 Histopathology of bone4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of bone4.166.1.3 Histopathology of bone4.166.1.3 Histopathology of bone4.166.1.4 Histopathology of bone4.166.1.4 Histopathology of heart2.086.1.4 Histopathology of heart2.087.1.4 Roditoring Threatense2.087.1.4 Roditographic changes2.08< | | |
| 31.5 Obesity0.693.6 Metabolic dysbiosis0.693.6 Metabolic dysbiosis0.694.1 Is the actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1 2 Cyclin activation (NF-rq, IL-6)1.254.1.2 Cyclin activation (ACCP generation and Hye activation)1.254.1.3 Fibre length of vistus medialis1.254.1.4 Fibre length of biczps femoris1.254.1.5 Radiographic changes1.254.1.6 Stadiographic changes1.254.1.6 Stadiographic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.1 Disability1.564.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.3 Receptor activation (TL-4, NLRP-3)1.565.4.4 Extra organ manifestation1.255.1 Which one (Methotrexate)4.165.3 I rest drug 11.385.3.1 Test drug 11.385.3.2 Test drug 21.385.3.3 Test drug 31.386.1 Histopatiological validation1.256.1 Histopatiology of bone4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of bone4.166.1.3 Histopathology of bone4.286.1.2 Histopathology of bone4.286.1.2 Histopathology of bone4.266.1.3 Histopathology of bone4.266.1.4 Histopathology of bone4.266.1.2 Histopathology of bone4.266.1.3 Histopathology of bone4.266.1.3 Histopathology of bone </td <td></td> <td></td> | | |
| 3.6 Metabolic dysbiosis0.694. Actiological validation12.54.1 Ste deciology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1.1 Cytokine activation (INF-a, IL-6)1.254.1.2 Cell infiltration (ACCP generation and Hyc activation)1.254.1.3 Fibre length of biceps femoris1.254.1.4 Strabe length of biceps femoris1.254.1.5 Radiographic changes1.254.1.6 Stabilization (ACCP generation and FQ and co-morbid conditions? If yes which one6.254.2 In Stability1.564.2.1 Disability changes1.564.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.3 Receptor activation (ILR-4, NLRP-3)1.565.4.4 Extra organ manifestation1.565.1 Are effective drugs in humans also effective in this model?4.165.1.1 Which one (Methotrexate)4.165.3.1 Test drug 13.385.3.3 Test drug 13.85.3.3 Test drug 31.385.3.3 Test drug 31.386.1.1 Histopathology of benet4.166.1.2 Histopathology of obenet4.166.1.2 Histopathology of obenet4.166.1.3 Histopathology of voltation2.257.1.4 Rediographic changes2.087.1.2 Perveptive changes2.087.1.2 Perveptive changes2.087.1.3 Cellular influencies are same or translatable to the clinical endpoints?6.257.1.3 Rediographic changes2.087.1.4 Rediographic banges2.08 <t< td=""><td></td><td></td></t<> | | |
| 4. Actiological Validation12.54.1 Is the actiology of the disease similar to human for Rheumatoid Arthritis? If yes which one6.254.1.1. Cytokine activation (INF-a, IL-6)1.254.1.2 Coll infiltration (ACCP generation and Hyc activation)1.254.1.3 Fibre length of vistus medialis1.254.1.4 Fibre length of biceps femoris1.254.1.5 Radiographic changes1.254.1 Is the actiology of the disease similar to human for RA and co-morbid conditions? If yes which one6.254.2 Is the actiology of the disease similar to human for RA and co-morbid conditions? If yes which one6.254.2.1 Disability1.564.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.3 Receptor activation (TLR-4, NLRP-3)1.565.4.4 Extra organ manifestation1.255.1 Are effective drugs as iso ineffective in this model?4.165.1 Which one (Methotrexate)1.385.3 Test drug 11.385.3.1 Test drug 21.385.3.2 Test drug 21.386.1 Histopathology of bone4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of bone4.166.1.3 Histopathology of bone4.166.1.4 Ristopathic sub activation sub istopathology2.087.1.2 Receptor validation1.2.57.1.4 Re endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.4 Ret disclast and biceps femoris muscle4.166.1.3 Histopathology of bone4.166.1.4 H | | |
| 41.1 Cytokine activation (TNF-q, IL-6)1.2541.2 Cell infiltration (ACCP generation and Hyc activation)1.2541.3 Fibre length of vistus medialis1.2541.4 Fibre length of vistus medialis1.2541.5 Ractiographic changes1.2542 Is the actiology of the disease similar to human for RA and co-morbid conditions? If yes which one6.2542.1 Disability1.5642.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.5642.3 Receptor activation (TLR-4, NLRP-3)1.5651.4 Are effective drugs in humans also effective in this model?4.1651.1 Which one (Methotrexate)4.1652.2 There flective drugs also ineffective in this model?4.1653.1 Test drug 11.3853.2 Test drug 21.3853.3 Test drug 31.385.3.3 Test drug 31.386.1 Histopathology of bneet4.166.1 Histopathology of breat4.166.1 Histopathology of breat4.166.1 Histopathology of vistus medialis and biceps femoris muscle4.166.1 Histopathology of vistus medialis and biceps femoris muscle4.166.1 Histopathology of vistus medialis and biceps femoris muscle2.087.1 Are the endpoints used in specifical studies are same or translatable to the clinical endpoints?6.257.1 Are the endpoints used in specifical endpoints comparable to the ones used to assess related clinical6.257.1 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.1 Are the methods | 4. Aetiological validation | |
| 1.2 Cell infiltration (ACCP generation and Hyc activation)1.254.1.3 Fibre length of vistus medialis1.254.1.4 Fibre length of biceps femoris1.254.1.5 Radiographic changes1.254.2 Is the actiology of the disease similar to human for RA and co-morbid conditions? If yes which one6.254.2.1 Disability1.564.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.3 Receptor activation (TLR-4, NLRP-3)1.564.2.4 Extra organ manifestation1.565. Pharmacological validation1.2.55. Inter effective drugs in humans also effective in this model?4.165.1 Are effective drugs as in ineffective in this model?4.165.1 Are effective drugs as in ineffective in this model?1.385.3 Test drug 11.385.3.1 Test drug 11.385.3.2 Test drug 21.386. Histopathological validation1.2.56. Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of heart4.166.1.3 Histopathology of heart4.166.1.3 Histopathology of heart2.087.1.1 Radiographic changes2.087.1.2 Perceptive change | 4.1 Is the aetiology of the disease similar to human for Rheumatoid Arthritis? If yes which one | 6.25 |
| 41.3 Fibre length of visus medialis1.2541.4 Fibre length of biceps femoris1.2541.5 Radiographic changes1.2542 Is the actiology of the disease similar to human for RA and co-morbid conditions? If yes which one6.2542.1 Disability1.5642.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.5642.3 Receptor activation (TLR-4, NLRP-3)1.5642.4 Extra organ manifestation1.565.1 Are effective drugs in humans also effective in this model?4.165.1 Are effective drugs also ineffective in this model?4.165.1 Are effective drugs also ineffective in this model?4.165.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?1.385.3.3 Test drug 21.385.3.3 Test drug 31.386. Histopathology of bone4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of heart4.166.1.3 Histopathology of heart4.166.1.3 Histopathology of heart4.166.1.3 Histopathology of heart4.166.1.4 Histopathology of heart4.287.1.1 Radiographic changes2.087.2 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.2 Are the endpoints used in preclinical endpoints comparable to the ones used to assess related clinical6.257.2 Preceptive changes2.082.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clin | 4.1.1 Cytokine activation (TNF- α , IL-6) | |
| 41.4 Fibre length of biceps femoris1.2541.5 Radiographic changes1.2542.5 Radiographic changes1.2542.1 Disability1.5642.2 Metabolic dysbiosis (Obesity, TG, LDL, HDL and fat accumulation in stool)1.5642.3 Receptor activation (TLR-4, NLRP-3)1.5642.4 Extra organ manifestation1.565.1 Are effective drugs in humans also effective in this model?4.165.1 Are effective drugs and ineffective in this model?4.165.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?4.165.3.1 Fast drug 11.385.3.2 Test drug 21.385.3.3 Test drug 11.385.3.3 Test drug 11.385.3.3 Test drug 11.385.3.3 Test drug 11.386. Histological validation12.56. 1.1 Histopathology of bone4.166.1.1 Histopathology of heart4.166.1.2 Histopathology of heare4.167.1 Radiographic changes2.087.1.2 Active drugs and interclual studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Active drugs disbuility1.047.2 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.2 Radiographic changes2.087.1.2 Active reflective in dispathology1.047.2 Are the endpoints used in stripters)1.047.2 Are the reflective in dispathology1.047.2 Are the endpoints used | | |
| 41.5 Radiographic changes1.2521 Is the actiology of the disease similar to human for RA and co-morbid conditions? If yes which one6.2542.1 Disability1.5642.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.5642.3 Receptor activation (TLR-4, NLRP-3)1.5642.4 Extra organ manifestation1.565. Pharmacological validation12.55.1 Are effective drugs in humans also effective in this model?4.165.1 Which one (Methotrexte)4.165.2 Are ineffective drugs also ineffective in this model?4.165.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?4.165.3 List drug 11.385.3.2 Test drug 21.385.3.2 Test drug 11.386.1 Bo the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of vistus medialis and biceps femoris muscle4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167.1.4 Ret endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.1.2 Perceptive changes2.087.1.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.1.4 Radiographic changes1.04 <td>-</td> <td></td> | - | |
| 4.2 Is the aetiology of the disease similar to human for RA and co-morbid conditions? If yes which one 6.25 4.2.1 Disability 1.56 4.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool) 1.56 4.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool) 1.56 4.2.4 Extra organ manifestation 1.56 5. Pharmacological validation 1.2.5 5.1 Are effective drugs in humans also effective in this model? 4.16 5.1.1 Which one (Methotrexate) 4.16 5.3.1 Test drug 1 1.38 5.3.2 Test drug 2 1.38 5.3.3 Test drug 3 1.38 6. Histological validation 12.5 6.1 Histopathology of heart 4.16 6.1.1 Histopathology of visus medialis and biceps femoris muscle 4.16 6.1.2 Histopathology of visus medialis and biceps femoris muscle 4.16 6.1.3 Histopathology of visus medialis and biceps femoris muscle 4.16 7.1.4 Radiographic changes 2.08 7.1.2 Perceptive changes 2.08 7.1.3 Cellular infiltration in histopathology 2.08 7.1.2 Perceptive changes 2.08 7.1.3 Cellular infiltration in histopathology <td< td=""><td></td><td></td></td<> | | |
| 4.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool)1.564.2.3 Receptor activation (TLR-4, NLRP-3)1.564.2.4 Extra organ manifestation1.565. Pharmacological validation1.2.55.1 Are effective drugs in humans also effective in this model?4.165.1.1 Which one (Methotrexate)4.165.2 Are ineffective drugs also ineffective in this model?4.165.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?4.165.3.1 rest drug 11.385.3.2 rest drug 21.385.3.3 rest drug 31.386. Histological validation1.2.56.1.1 Histopathology of baret4.166.1.2 Histopathology of bare4.166.1.3 Histopathology of bare4.166.1.3 Histopathology of stuts medialis and biceps femoris muscle1.67.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology0.087.2.4 New Nume (pain and stiffness)1.047.2.5 Symmetric progression1.047.2.5 Symmetric progression1.047.2.5 Atter genetic biochemical markers (Lipid Profile)1.047.2.5 Atterogenic biochemical markers (Lipid Profile)1.047.2.5 Atterogenic biochemical markers (Lipid Profile)1.047.2.5 Sthis species also have orthologous genes and | 4.2 Is the aetiology of the disease similar to human for RA and co-morbid conditions? If yes which one | |
| 4.2.3 Receptor activation (TLR-4, NLRP-3)1.564.2.4 Extra organ manifestation1.2.55. Pharmacological validation12.55.1 Are effective drugs in humans also effective in this model?4.165.1.1 Which one (Methotrexate)4.165.2 Are ineffective drugs also ineffective in this model?4.165.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?4.165.3.1 Test drug 11.385.3.2 Test drug 21.386.1 Stotigical validation12.56.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.3 Histopathology of bone4.166.1.3 Histopathology of heart4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?2.087.1.2 Perceptive changes2.087.1.2 Perceptive changes2.087.2 Are the endpoints used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2 Avalking disability1.047.2.4 Severity of disease1.047.2.5 Objective disease1.047.2.6 Objective disease1.047.2.5 Atter endpoints comparable to the orthogous genes/noticinical1.047.2 Valking disability1.047.2.5 Atter orgenic biochemical markers (Lipid Profile)1.047.2.6 Objective and metabolic dysbiosis1 | 4.2.1 Disability | 1.56 |
| 4.2.4 Extra organ manifestation1.565. Pharmacological validation12.55.1 Are effective drugs in humans also effective in this model?4.165.1.1 Which one (Methotrexate)4.165.2 Are ineffective drugs also ineffective in this model?4.165.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?4.165.3 Test drug 11.385.3.2 Test drug 21.385.3.3 Test drug 31.386. Histological validation12.56. I histopathology of bone4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of visus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Symmetric progression1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Obesity and metabolic dysbiosis1.048. Genetic validation12.58. 1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168. 2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins1.047.2.5 Atterogenic biochemical | 4.2.2 Metabolic dysbiosis (Obesity, TG, TC, LDL, HDL and fat accumulation in stool) | |
| 5. Pharmacological validation 12.5 5.1 Are effective drugs in humans also effective in this model? 4.16 5.1.1 Which one (Methotrexate) 4.16 5.2 Are ineffective drugs also ineffective in this model? 4.16 5.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model? 4.16 5.3.1 Test drug 1 1.38 5.3.2 Test drug 2 1.38 5.3.3 Test drug 3 1.38 6. Histological validation 12.5 6.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one 4.16 6.1.2 Histopathology of heart 4.16 6.1.3 Histopathology of heart 4.16 6.1.4 Histopathology of vistus medialis and biceps femoris muscle 4.16 7.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints? 6.25 7.1.1 Ractiographic changes 2.08 7.1.2 Perceptive changes 2.08 7.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical 6.25 7.2.1 Paw volume (pain and stiffness) 1.04 7.2 Ave the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical <td< td=""><td>•</td><td></td></td<> | • | |
| 5.1 Are effective drugs in humans also effective in this model? 4.16 5.1.1 Which one (Methotrexate) 4.16 5.2 Are ineffective drugs also ineffective in this model? 4.16 5.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model? 4.16 5.3.1 Test drug 1 1.38 5.3.2 Test drug 2 1.38 6.1 Stological validation 12.5 6.1 Bot the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one 4.16 6.1.1 Histopathology of bone 4.16 6.1.2 Histopathology of visus medialis and biceps femoris muscle 4.16 6.1.3 Histopathology of visus medialis and biceps femoris muscle 4.16 7.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints? 6.25 7.1.1 Actiographic changes 2.08 7.1.2 Perceptive changes 2.08 7.1.3 Cellular infiltration in histopathology 2.08 7.2.4 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical 6.25 7.2.1 Paw volume (pain and stiffness) 1.04 7.2.2 Symmetric progression 1.04 7.2.3 Symmetric progression 1.04 | | |
| 5.1.1 Which one (Methotrexate) 4.16 5.2 Are ineffective drugs also ineffective in this model? 4.16 5.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model? 4.16 5.3.1 Test drug 1 1.38 5.3.2 Test drug 2 1.38 5.3.3 Test drug 3 1.38 6. Histological validation 12.5 6.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one 4.16 6.1.1 Histopathology of bone 4.16 6.1.2 Histopathology of bone 4.16 6.1.3 Histopathology of vistus medialis and biceps femoris muscle 4.16 7.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints? 6.25 7.1.1 Radiographic changes 2.08 7.1.2 Perceptive changes 2.08 7.1.3 Cellular infiltration in histopathology 6.25 7.2.1 Paw volume (pain and stiffness) 1.04 7.2.2 Walking disability 1.04 7.2.3 Symmetric progression 1.04 7.2.4 Severity of disease 1.04 7.2.5 Atherogenic biochemical markers (Lipid Profile) 1.04 7.2.5 Obesity and metabolic dysbiosis | - | |
| 5.3 Have drugs with different mechanisms of action and acting on different pathway been tested in this model?4.165.3.1 Test drug 11.385.3.2 Test drug 21.385.3.3 Test drug 31.386. Histological validation12.56.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of heart4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Othering in biolochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58. 10 bes this species also have orthologous genes and /or proteins involved in the human disease4.168. 2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 5.1.1 Which one (Methotrexate) | |
| 5.3.1 Test drug 11.385.3.2 Test drug 21.385.3.3 Test drug 31.386. Histological validation12.56.1 Bo the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of heart4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167.1 Are the endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 5.2 Are ineffective drugs also ineffective in this model? | 4.16 |
| 5.3.2 Test drug 21.385.3.3 Test drug 31.386. Histological validation12.56.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of vistus medialis and biceps femoris muscle4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | | |
| 5.3.3 Test drug 31.386. Histological validation12.56.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of heart4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Othersene to biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | | |
| 6. Histological validation12.56.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of vistus medialis and biceps femoris muscle4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 6 | |
| 6.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one4.166.1.1 Histopathology of bone4.166.1.2 Histopathology of vistus medialis and biceps femoris muscle4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167.1 Are the endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | - | |
| 6.1.1 Histopathology of bone4.166.1.2 Histopathology of heart4.166.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167.1 And the endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Reverity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 6.1 Do the histopathological structures in relevant tissues resemble the ones found in humans? If yes which one | |
| 6.1.3 Histopathology of vistus medialis and biceps femoris muscle4.167. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 6.1.1 Histopathology of bone | |
| 7. Endpoint validation12.57.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 6.1.2 Histopathology of heart | |
| 7.1 Are the endpoints used in preclinical studies are same or translatable to the clinical endpoints?6.257.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | | |
| 7.1.1 Radiographic changes2.087.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | • | |
| 7.1.2 Perceptive changes2.087.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | | |
| 7.1.3 Cellular infiltration in histopathology2.087.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical6.257.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 7.1.2 Perceptive changes | |
| 7.2.1 Paw volume (pain and stiffness)1.047.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 7.1.3 Cellular infiltration in histopathology | |
| 7.2.2 Walking disability1.047.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 7.2 Are the methods used to assess preclinical endpoints comparable to the ones used to assess related clinical | |
| 7.2.3 Symmetric progression1.047.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 7.2.1 Paw volume (pain and stiffness) | |
| 7.2.4 Severity of disease1.047.2.5 Atherogenic biochemical markers (Lipid Profile)1.047.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | 7.2.2 Walking disability | |
| 7.2.5 Atherogenic biochemical markers (Lipid Profile) 1.04 7.2.6 Obesity and metabolic dysbiosis 1.04 8. Genetic validation 12.5 8.1 Does this species also have orthologous genes and /or proteins involved in the human disease 4.16 8.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins 4.16 | | |
| 7.2.6 Obesity and metabolic dysbiosis1.048. Genetic validation12.58.1 Does this species also have orthologous genes and /or proteins involved in the human disease4.168.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins4.16 | | |
| 8. Genetic validation 12.5 8.1 Does this species also have orthologous genes and /or proteins involved in the human disease 4.16 8.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins 4.16 | | |
| 8.1 Does this species also have orthologous genes and /or proteins involved in the human disease 4.16 8.2 If so, are the relevant genetic mutations or alterations also present in the orthologous genes/proteins 4.16 | 8. Genetic validation | |
| | 8.1 Does this species also have orthologous genes and /or proteins involved in the human disease | |
| 8.3 If so, is the expression of such orthologous genes and/ or proteins similar to the human condition? 4.16 | | 4.16 |

Results and Discussion

Results of model validation for RA

Models developed for RA were compared here to select the best model with a higher validity score, where Model I (CFA 0.1 mL+LPS 10 μ g/mL) secured a moderately validated score 64% with the highest uncertainty factor of 36% and Model II (collagen 0.1 mL+LPS 10 μ g/mL) secured s highly validated score of 82%, which shows the maximum clinical resemblance for RA with clinical situations. Moreover, the uncertainty factor for this model was 18%, which gives the accounts of symptomatology, biochemical estimation histological data and endpoint results domain, which are not common on the radar plot. Model II (collagen 0.1 mL+LPS 10 μ g/mL) highly resembles human RA-like conditions and these validity scores suggest its validity in terms of severity and disease progression. The similarity factors were also calculated between these two models, which shows the points in domains where both the models have 29% similar representations of RA, which includes epidemiological, genetic and aetiological validation domains and they are similar throughout the model development with all the inducers (Figure 2).





Figure 2. Radar plot for comparison between models developed for Rheumatoid arthritis.

Results of model validation among RA models and CVD in RA models

The statistical data showed that there is a potential of developing cardiovascular complication in comparative groups; model I (CFA 0.1 mL+LPS 10 μ g/mL), model II (CIA 0.1 mL+LPS 10 μ g/ml), model III (CFA 0.1 mL+LPS 10 μ g/mL+HFD), and model IV (collagen 0.1 mL+LPS 10 μ g/mL+HFD), which were compared for

optimizing the interconnecting parameters responsible for progression of cardiovascular complications in existing RA. In final comparison, model IV (collagen 0.1 mL+LPS 10 μ g/mL+HFD) secured a higher validation score of 95%, and the uncertainty factor was 5%, which proves that model IV has maximum resemblance with clinical situations. All these four models have some similar domains as the similarity factor among all the groups is 18% (Figure 3, Table 2).



| Validation | Model I (CFA 0.1 mL+ LPS 10 µg/mL) | Model II (Collagen 0.1 mL+ LPS 10 µg/mL) | Model III (CFA 0.1 mL+ LPS 10 µg/mL+HFD) | Model IV (Collagen 0.1 mL+ LPS 10 µg/mL+HFD) | |
|---|--|--|--|--|--|
| 1. Epidemiological validation | 0.3 | 0.3 | 0.2 | 0.2 | |
| 2. symptomatology and natural history (SNH) | 0.2 | 0.5 | 0.5 | 0.9 | |
| 3. Biochemical Validation | 0.5 | 0.6 | 0.6 | 0.9 | |
| 4. Aetiological Validation | 0.5 | 0.5 | 0.5 | 0.9 | |
| 5. Pharmacological Validation | 0.4 | 0.6 | 0.5 | 0.5 | |
| 6. Histological Validation | 0.5 | 0.6 | 0.5 | 0.9 | |
| 7. Endpoint Validation | 0.4 | 0.5 | 0.6 | 0.9 | |
| 8. Genetic Validation | 0.2 | 0.2 | 0.2 | 0.2 | |
| | Interp | pretations from radar values | | | |
| Uncertainty Factor | 36 % | 18 % | 12 % | 5 % | |
| Similarity Factor | 18 % | | | | |
| Validation Score | 64 % | 82 % | 88 % | 95 % | |

Table 2. Score of same weight score obtained as ratio by FIMD questionnaire of RA models and CVD in RA models

Results of model validation for best fit with human disease resemblance

The final comparison was done for optimizing a single model which can mimic the clinical symptoms of cardiovascular complications in patients suffering from RA. The objective was completed by comparison between the representative model of RA (collagen 0.1 mL+LPS 10 μ g/mL) with representative model of RA with cardiovascular complications (collagen 0.1 mL+LPS 10 μ g/mL+HFD) and the models represent 5% of similarities, which show the interconnection between both the diseases in terms of disease progression (Figure 4).




Figure 4. Radar plot for final comparison between Rheumatoid arthritis and models developed for cardiovascular complications in Rheumatoid arthritis for best fit with human disease resemblance.

Conclusion

On the basis of radar plot estimation, the comparison and model validation showed that in RA models – CFA with LPS (10 μ g/mL) – have potential to represent RA but the translational competence of this model is moderate; disease symptoms are not created as in human situations. Whereas the groups sensitized with collagen with LPS (10 μ g/mL) proved to give higher impressions of RA with higher similar factors in terms of resemblance of human deformities as secondary lesions and deformed bones in radiographic analysis, and these data were further confirmed with histopathological analysis.

In RA with CVD complications, models developed with HFD, CIA and LPS (10 μ g/mL), when compared with other groups, were found to give higher interconnecting links of cardiovascular complications with RA as these models showed the high elevation in prevalidation parameters evaluated for RA (Anti-CCP, Paw volume, ESR, CRP TNF- α , IL-6, X-ray, histopathology of bone) and prevalidation parameters evaluated for CVD (Homocysteine levels, NF- κ B, TLR-4, TG, TC, HDL, LDL, histopathology of vastus medialis and biceps femoris muscle).

On the basis of the above interpretations, we can conclude that model II (collagen 0.1 mL+LPS 10 μ g/mL) is a highly validated model for Rheumatoid Arthritis with

References

- Barnett MJ, Doroudgar S, Khosraviani VIp EJ (2022) Multiple comparisons: To compare or not to compare, that is the question. Research in Social and Administrative Pharmacy 18(2): 2331–2334. https://doi.org/10.1016/j.sapharm.2021.07.006 [PubMed]
- Cassotta M, Pistollato F, Battino M (2020) Rheumatoid arthritis research in the 21st century: Limitations of traditional models, new technologies, and opportunities for a human biology-based approach. ALTEX-Alternatives to Animal Experimentation 37(2): 223–242. https://doi.org/10.14573/altex.1910011 [PubMed]
- Deore AB, Dhumane JR, Wagh R, Sonawane R (2019) The stages of drug discovery and development process. Asian Journal of Pharmaceutical Research and Development 7(6): 62–67. https:// doi.org/10.1111/bph.15178
- Dobbin KK, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, Masucci GV, Robbins PB, Selvan SR, Streicher HZ (2016) Validation of biomarkers to predict response to immunotherapy in cancer: Volume II – clinical validation and regulatory considerations. Journal for Immunotherapy of Cancer 4(1): 1–14. https://doi.org/ 10.1186/s40425-016-0178-1 [PubMed] [PMC]
- Dubey T, Chorawala M (2015) Lipopolysaccharide (LPS) and Muramyl dipeptide (MDP) induced chronic liver injury in high fat diet fed rat-a possible model for non alcoholic fatty liver disease. International Journal of Pharmaceutical Sciences and Research 6(8): 3401. https://doi.org/10.13040/IJPSR.0975-8232.6(8).3401-11
- Ferreira GS, Veening-Griffioen DH, Boon WP, Moors EH, Gispende Wied CC, Schellekens H, van Meer PJ (2019) Correction: A standardized framework to identify optimal animal models for efficacy assessment in drug development. PloS One 14(7): e0220325. https://doi.org/10.1371/journal.pone.0218014 [PubMed] [PMC]
- Ferreira GS, Veening-Griffioen DH, Boon WP, Moors EH, van Meer PJ (2020) Levelling the translational gap for animal to human efficacy data. Animals 10(7): 1199. https://doi.org/doi:10.3390/ ani10071199 [PubMed] [PMC]
- Hong J-I, Park IYKim HA (2020) Understanding the molecular mechanisms underlying the pathogenesis of arthritis pain using animal models. International Journal of Molecular Sciences 21(2): 533. https://doi.org/10.3390/ijms21020533 [PubMed] [PMC]

maximum human resemblance to inflammatory and immune component involvements. Another conclusion is that LPS in a 10 μ g/ml dose can be used along with CFA and collagen to induce RA in animals. In the final comparison, we can draw the conclusion that HFD and LPS can be incorporated with collagen to develop atherogenic conditions in RA, as model IV (collagen 0.1 mL+LPS 10 μ g/mL+HFD) is proved to be a highly validated and optimized model for cardiovascular complications in stable RA with the maximum insight into the clinical situation on the basis of the FIMD validation method.

Conflict of interest

The authors declare that they have no conflicts of interest to disclose.

Acknowledgments

We want to acknowledge the Government of India, Ministry of Science and Technology, Department of Science and Technology (WISE KIRAN DIVISION) for funding this research work under the Women Scientist Scheme (WOS-A) with section order no. SR/WOS-A/ LS-195/2018.

Data availability

All of the data that support the findings of this study are available in the main text or Supplementary information.

- Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdah R Baumans V, Desaintes C, Di Santo J, Distler J, Garside P (2011) Animal models for arthritis: Innovative tools for prevention and treatment. Annals of the Rheumatic Diseases 70(8): 1357–1362. http://dx.doi.org/10.1136/ard.2010.148551 [PubMed]
- Lilley E, Stanford SC, Kendall DE, Alexander SP, Cirino G, Docherty JR, George CH, Insel PA, Izzo AA, Ji Y (2020) Arrive 2.0 and the British journal of pharmacology: Updated guidance for 2020. British Journal of Pharmacology 177(16): 3611. https://doi.org/10.1111/bph.15178 [PubMed] [PMC]
- Luo X, Cui J, Long XChen Z (2020) TLRs play crucial roles in regulating RA synoviocyte. Endocrine, Metabolic & Immune Disorders-Drug Targets 20(8): 1156–1165. https:// doi.org/10.2174/1871530320666200427115225 [PubMed]
- Miyoshi M, Liu S (2024) Collagen-induced Arthritis Models Rheumatoid Arthritis: Methods and Protocols. Springer, pp. 3-7. https://doi.org/10.1007/978-1-4939-8802-0_1
- Sams-Dodd F (2006) Strategies to optimize the validity of disease models in the drug discovery process. Drug Discovery Today 11(7-8): 355-363. https://doi.org/10.1016/ j.drudis.2006.02.005 [PubMed]
- Scannell JW, Bosley J, Hickman JA, Dawson GR, Truebel H, Ferreira GS, Richards D, Treherne JM (2022) Predictive validity in drug discovery: What it is, why it matters and how to improve it. Nature Reviews Drug Discovery 21(12): 915– 931. https://doi.org/10.1038/s41573-022-00552-x [PubMed]
- Silverman J, Nithianantharajah J, Der-Avakian A, Young J, Rizzo SS (2020) Lost in translation: At the crossroads of face validity and translational utility of behavioral assays in animal models for the development of therapeutics. Neuroscience and Biobehavioral Reviews 116: 452. https:// doi.org/10.1016/j.neubiorev.2020.07.008 [PubMed] [PMC]
- Tadenev AL, Burgess RW (2019) Model validity for preclinical studies in precision medicine: Precisely how precise do we need to be? Mammalian Genome 30(5): 111– 122. https://doi.org/10.1007/s00335-019-09798-0 [PubMed] [PMC]

Author contributions

- Trupti Dubey, M. Pharm, Ph.D Research scholar (Pharmacology), Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India; e-mail: truptidubey20@gmail.com; ORCID ID https://orcid.org/0000-0003-3116-0042. The author's contribution: fund acquisition, visualization and formal analysis of investigational research, model validation, data curation, and writing of the original draft.
- Kirti V. Patel, M. Pharm, Ph.D (Pharmacology) Associate Professor, Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India; e-mail: kirtipatel.pub2023@gmail.com; ORCID ID https://orcid.org/0000-0002-9224-1762. The author's contribution: supervision of research work, project administration, conceptualization, review and editing of the manuscript.

Supplementary material 1

Details of study design I and II with preliminary (prevalidation) results

Authors: Trupti Dubey, Kirti V. Patel Data type: pdf

Copyright notice: This dataset is made available under the Open Database License (http://opendatacommons.org/ licenses/odbl/1.0/). The Open Database License (ODbL) is a license agreement intended to allow users to freely share, modify, and use this Dataset while maintaining this same freedom for others, provided that the original source and author(s) are credited.

Link: https://rrpharmacology.ru/index.php/journal/article/view/446/506

Supplementary material 2

Questionnaire details for comparison and validation of models for RA and CVD in RA

Authors: Trupti Dubey, Kirti V. Patel Data type: pdf

Copyright notice: This dataset is made available under the Open Database License (http://opendatacommons.org/ licenses/odbl/1.0/). The Open Database License (ODbL) is a license agreement intended to allow users to freely share, modify, and use this Dataset while maintaining this same freedom for others, provided that the original source and author(s) are credited.

Link: https://rrpharmacology.ru/index.php/journal/article/view/446/507

Supplementary material 3

FIMD domain wise calculations for model validation

Authors: Trupti Dubey, Kirti V. Patel Data type: pdf

Copyright notice: This dataset is made available under the Open Database License (http://opendatacommons.org/ licenses/odbl/1.0/). The Open Database License (ODbL) is a license agreement intended to allow users to freely share, modify, and use this Dataset while maintaining this same freedom for others, provided that the original source and author(s) are credited.

Link: https://rrpharmacology.ru/index.php/journal/article/view/446/508

Supplementary material 4

Final FIMD validation calculations for radar plot estimation and comparison to select best model for CVD in RA

Authors: Trupti Dubey, Kirti V. Patel

Data type: xlsx

Copyright notice: This dataset is made available under the Open Database License (http://opendatacommons.org/ licenses/odbl/1.0/). The Open Database License (ODbL) is a license agreement intended to allow users to freely share, modify, and use this Dataset while maintaining this same freedom for others, provided that the original source and author(s) are credited.

Link: https://rrpharmacology.ru/index.php/journal/article/view/446/version/446